Tpex

Tpex (TCF1+ Progenitor-Exhausted T cell)

一行要約

Tpex は TCF1 (TCF7)+ SLAMF6+ PD-1 intermediate な CD8 T-cell 亜集団で、慢性抗原刺激 (LCMV chronic, tumor) 下で形成される 長期 self-renewing で IO 応答性の core を担う 「stem-like exhausted progenitor」。Im et al. Nature 2016 / Miller 2019 Nat Immunol / Siddiqui 2019 Immunity が確立、PD-1 blockade 応答の primary effector source は Tpex → Tex-int 分化軸であることが示された。Tumor draining LN / TLS 内に主に存在、IO 応答性予測の central biomarker / 治療標的として現在最大級の関心を集める T-cell state。

主要エビデンス

• Im et al. Nature 2016 (Nature): LCMV chronic で TCF1+ stem-like CD8 が PD-1 blockade 応答の主役、self-renewal + Tex differentiation を担うことを証明 (paradigm-setting)
• Miller 2019 (Nat Immunol): tumor で TCF7+ progenitor が IO 応答 source、TCF1+ → TCF1− Tex 分化階層を atlas
• Siddiqui 2019 (Immunity): Tpex が PD-1 blockade 応答の central であり、Tex-terminal は anti-PD-1 に応答しないことを mechanistically 証明
• Pauken 2016 (Science): exhaustion epigenetic landscape は PD-1 blockade 後も維持されるが、Tpex は新規 effector clone を継続供給
• Eberhardt 2021 (Nature): human melanoma で TCF7+ stem-like CD8 と IO benefit の clinical correlation
• TLS 内 Tpex: TLS-resident Tpex pool が IO 応答性 / long-term durability の anatomical basis (Cabrita 2020 Nature; Helmink 2020 Nature)

メカニズム

Tpex は naive / memory CD8 と異なる 慢性抗原 + co-inhibitory signaling 下の不完全 differentiation state。Key TF: TCF7 (TCF1), BACH2, ID3, BCL6 が self-renewal / progenitor program を維持、TBX21 (T-bet) は intermediate level、TOX / NR4A1 / IRF4 は exhaustion master regulator (Tex 全般共通)。Surface phenotype: PD-1 intermediate, SLAMF6 +, CXCR5 +, TIM-3 −, LAG-3 −, CD39 −, TCF1 +, polyfunctional cytokine 産生力保持 (vs Tex-terminal で枯渇)。

Tpex → Tex-int → Tex-term の hierarchical differentiation: IL-12 / antigen / co-stim 環境で Tex-int (TCF1−, TIM-3+, polyfunctional) を生成し effector function を担う。PD-1 blockade は Tpex → Tex-int proliferation / effector differentiation を accelerate するが、Tex-term は不可逆的 exhaustion (epigenetic fixation) で応答せず。

Tumor 内分布: tumor draining LN / TLS で Tpex 高密度, intratumor では Tex-int / Tex-term dominant。TCR clonotype は tumor draining LN Tpex から intratumor Tex-int / Tex-term に流れ、IO 応答下で systemic clonal replacement (Yost et al. NatMed 2019 Nat Med “clonal replacement”) を実現。

臨床位置づけ

Tpex frequency / TCF1+ CD8 ratio は anti-PD-1 応答性の central predictive biomarker として確立、CITE-seq / multiplex IF で routinely 測定。TLS density / B-cell maturation と Tpex は co-localize、IO benefit の anatomical basis を提供。治療応用:

1. CAR-T 製品の Tpex / stem-like population enrichment が in vivo expansion / persistence と相関 (Fraietta 2018, Zhao et al. NatCancer 2025 等)
2. TIL therapy: Tpex-enriched TIL product の clinical efficacy improvement
3. Adoptive transfer 前の Tpex polarization (IL-7 / IL-21 / Wnt activator) の研究進行
4. IL-2 mutein (NKTR-358 等) で Tpex maintenance
5. TCF1+ Tpex を target に CD8 epitope vaccine を設計

Open Questions

• Tpex maintenance / expansion の薬剤学的介入 (cytokine, Wnt, BCL6 modulator)
• Tumor-resident Tpex vs LN-resident Tpex の機能的差異
• Brain metastasis での Tpex の存在 / 機能 (CNS-specific exhaustion landscape)
• CAR-T / TIL 製品設計 での Tpex enrichment optimal protocol
• Tpex-specific therapeutic targeting: agonist (IL-7 / IL-15 / IL-21 / 4-1BB) の subset-specific delivery
• Aging / chronic inflammation が Tpex pool に与える long-term impact

関連エンティティ

• 関連細胞: CD8-T-cell / Exhausted-CD8-T-cell / CD4-T-helper-cell / Tfh-cell / CAR-T-cell / Drug-tolerant-persister
• 関連経路: PD-1-PD-L1-signaling-pathway / CTLA-4-B7-signaling-pathway / Antigen-presentation-pathway / JAK-STAT-pathway
• 関連サイトカイン: IFN-gamma / IL-2 / IL-7 / IL-15 / IL-21 / CXCL13
• 関連薬剤: PD-1-inhibitor / CTLA-4-inhibitor / CAR-T-therapy / TCR-T-therapy / TIL-therapy / Cancer-vaccine / mRNA-vaccine
• 関連手法: CITE-seq / scRNA-seq / TCR-seq / Multiome / scATAC-seq / CODEX-PhenoCycler
• 関連概念: T-cell-exhaustion / Tertiary-lymphoid-structure / IO-primary-resistance / IO-acquired-resistance / Tumor-immune-microenvironment-classification

関連論文

Basic-Brain metastasis

• Rodriguez-Baena et al. CancerCell 2025 — Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases
• Wischnewski et al. NatCancer 2023 — Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation

Basic-Extracellular vesicles

• Greening et al. NatRevClinOncol 2025 — Clinical relevance of extracellular vesicles in cancer-therapeutic and diagnostic potential

Basic-Immunotherapy

• Kamigaichi et al. CancerImmunolImmunother 2026 — Immunological impact of tumor-draining lymph node dissection on systemic th1-like CD4+ T cells in patients with
• Burger et al. Cell 2021 — Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors
• Scharping et al. Cell 2026 — Proteostasis sustains t cell differentiation potential and tumor-infiltrating lymphocyte function
• Sakuishi et al. JExpMed 2010 — Targeting Tim-3 and PD-1 pathway to restore anti-tumor immunity
• Mann et al. NatImmunol 2019 — Tick-TOX, it’s time for T cell exhaustion
• Labarta-Bajo et al. NatImmunol 2021 — BAtCHing stem-like T cells during exhaustion
• Chen et al. Nature 2017 — Elements of cancer immunity and the cancer-immune set point
• Li et al. Nature 2026 — SLAMF6 as a drug-targetable suppressor of t cell immunity against cancer
• Li et al. SciImmunol 2026 — Citraconate preserves T cell stemness and antitumor immunity
• Slater et al. TrendsCancer 2026 — Epigenetic, epitranscriptomic, and metabolic control of t cell exhaustion

Basic-Neutrophil and myeloid cell

• He et al. ChinMed 2026 — Shuangshen granules enhance anti-PD1 therapy effectiveness in lung adenocarcinoma by modulating myeloid-derived

Clinical-Novel modalities

• Krishna et al. NatRevImmunol 2026 — Hallmarks and correlates of effective adoptive cell immunotherapy for cancer